.jpg)
4 hours ago
1
Article content
The company receives additional non-dilutive funding from Natural Products Canada.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
TORONTO — Ostia Sciences Inc., a microbiome therapeutics company developing next-generation probiotics, today announced the successful close of its seed financing round, raising CAD $1.46 million as of December 31, 2024.
Article content
Article content
In addition to private investment, Ostia secured over $393,000 in non-dilutive grants, including $350,000 from Natural Products Canada (NPC) through its Proof-of-Concept (POC) program.
Article content
Article content
The NPC POC funding will help advance Ostia’s planned clinical trials, focusing on natural solutions for widespread conditions like gingivitis, halitosis, and treatment-related oral complications of head and neck cancer patients.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Our progress reflects both strong investor confidence and essential support from Canadian innovation programs, enabling the commercialization of natural health solutions and helping millions of patients worldwide,” said Dr. Abdelahhad Barbour, CEO of Ostia Sciences. “We now have the resources to optimize our manufacturing processes and move SALI-10 toward clinical validation.”
Article content
With full ownership of its IP portfolio, an expanding team of advisors, and a robust discovery pipeline, Ostia Sciences is positioning itself as a leader in microbiome-based biotherapeutics.
Article content
“We’re building more than just a product, we’re creating a platform for targeted, microbiome-driven drug development,” said Dr. Michael Glogauer, Chief Scientific Officer. “This funding brings us one step closer to transforming how we treat oral and respiratory diseases.”
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
For more information
Article content
Article content
English (US)